With a winning combination of outstanding research, a proven track record and talented analysts, we create a truly compelling proposition for investors. GeoInvesting’s investment solutions come from a place of innovation and a commitment to risk management.
By Maj Soueidan, Co-founder, GeoInvesting
I began my full-time investor career path while in college between 1988 to 1992. From time to time, I find myself struggling to shed some of the bad habits that get in the way of maximizing my investment experience. I think a lot of investors can sympathize with these problems, so I decided to make a top ten list of rules to follow for those that are thinking about becoming a full-time investor. Hopefully, this will help you learn from my experience. Read the entire article here…
More Educational Content – Check Back Often!
We recently wrote an in depth research piece on Rand Worldwide Inc (OOTC:RWWI) supporting our long disclosure in the stock. It was one of our more near-term picks that we published to our pro portal to help our members learn more about the reasons why we like RWWI. If you're already a member and need [...]
Posted: May 12, 2019
Tito’s and Nachos A few Fridays ago, after work, I went to a relatively new Mexican restaurant in Las Olas called El Camino, with a friend of mine, Ed. Las Olas is situated in downtown Fort Lauderdale between Fort Lauderdale Beach and the Riverfront, where the spring breakers, college kids and tourists hang out. It’s [...]
Posted: May 11, 2019
In his book Good to Great, Jim Collins introduces the concept of the “Big Hairy Audacious Goal” A Big Hairy Audacious Goal (BHAG, pronounced BEE-hag) is a strategic business statement similar to a vision statement which is created to focus an organization on a single medium- to long-term organization-wide goal which is audacious, likely to [...]
Posted: May 3, 2019
One of the unique things that sets GeoInvesting’s service apart from other research firms isn’t just the institutional quality of our research – but the fact that we provide it to our members as we work to undertake it. This means that our members get a “cradle to grave” view of our research methodology every [...]
Posted: April 9, 2019
One of the strongest performing biopharmaceutical stocks this year is Evolus (EOLS). When the FDA on February 1 approved the company’s lead product Jeuveau, a potential Botox competitor, the stock shot up to about $25 per share. Since then its shares have held stable, even touching $30 per share. SanaCurrents, which tracks market-moving catalysts of [...]
Posted: March 25, 2019
Viewing page 1 of 3|Next Page